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stable cell line (GT2-LPk) derived from LLC-Pk was
created in which endogenous DNA topoisomerase
II
 
  
 
(topoII
 
 
 
) protein was downregulated and replaced
by the expression of topoII
 
 
 
 fused with enhanced green
ﬂuorescent protein (EGFP–topoII
 
 
 
). The EGFP–topoII
 
 
 
faithfully mimicked the distribution of the endogenous
protein in both interphase and mitosis. In early stages of
mitosis, EGFP–topoII
 
 
 
 accumulated at kinetochores and in
axial lines extending along the chromosome arms. During
anaphase, EGFP–topoII
 
 
 
 diminished at kinetochores and
increased in the cytoplasm with a portion accumulating
into large circular foci that were mobile and appeared to fuse
with the reforming nuclei. These cytoplasmic foci appearing
A
 
at anaphase were coincident with precursor organelles of
the reforming nucleolus called nucleolus-derived foci
(NDF). Photobleaching of EGFP–topoII
 
 
 
 associated with
kinetochores and chromosome arms showed that the majority
of the protein rapidly exchanges (t1/2 of 16 s). Catalytic
activity  of topoII
 
 
 
  was essential for rapid dynamics, as
ICRF-187, an inhibitor of topoII
 
 
 
, blocked recovery after
photobleaching. Although some topoII
 
 
 
  may be stably
associated with chromosomes, these studies indicate that
the majority undergoes rapid dynamic exchange. Rapid
mobility of topoII
 
 
 
 in chromosomes may be essential to
resolve strain imparted during chromosome condensation
and segregation.
 
Introduction
 
DNA topoisomerase II (topoII)* is essential in proliferating
cells and is a major target for many anticancer drugs (Bakshi
et al., 2001; Wang et al., 2001). In mammals, two genes
code for isoforms of topoisomerase II, termed 
 
 
 
 and 
 
 
 
, and
alternative splicing confers further diversity (Petruti-Mot and
Earnshaw, 2000). TopoII has been proposed to play both
catalytic and structural roles in mitotic chromosome segre-
gation. Genetic studies in yeast and inhibitor studies in
mammalian cells suggest that topoII is required to resolve sister
chromatid catenations during separation of the chromatids
(Uemura et al., 1987; Holm et al., 1989; Gorbsky, 1994). In
chromosomes that have been isolated from cells arrested in
M phase, the bulk of topoII is tightly associated, suggesting
that topoII forms a stable structural component or scaffold of
chromosome architecture (Earnshaw et al., 1985). A study of
rhodamine-labeled topoII in 
 
Drosophila 
 
embryos challenged
this model with evidence that much topoII diffuses from the
chromosomes at progressive stages of mitosis (Swedlow et al.,
1993). The stability of topoII
 
 
 
 protein is cell cycle regulated,
high during G2/M phases, and becoming unstable in the
subsequent G1 phase (Heck et al., 1988).
Some immunolocalization and electron microscopy studies
show a distribution of topoII in an axial core extending the
length of the chromosome (for review see Warburton and
Earnshaw, 1997). However, in both 
 
Drosophila 
 
embryos and
condensed chromosomes formed in vitro in 
 
Xenopus
 
 extracts,
topoII shows more uniform distribution on the chromosome
arms (Hirano and Mitchison, 1993; Swedlow et al., 1993).
In some immunolabeling studies, the enzyme was reported to
be concentrated at kinetochores (Taagepera et al., 1993;
Gorbsky, 1994; Rattner et al., 1996; Sumner, 1996). In
interphase mammalian cells, various groups report differences
in the subnuclear distribution of topoII
 
  
 
with some but not
all studies noting a concentration in the nucleoli (Meyer et
al., 1997; Khelifa and Beck, 1999; Mo and Beck, 1999).
To investigate the dynamics of topoII
 
 
 
 in living cells, we
produced a stable cell line expressing EGFP–topoII
 
 
 
. FRAP
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experiments show that most topoII
 
 
 
  exchanges rapidly
between cytoplasmic and kinetochore/chromosome-bound
pools, and thus does not constitute a static structural chro-
mosome scaffold. We also report a novel localization of to-
poII
 
 
 
 in late anaphase and telophase to discrete cytoplasmic
foci that appear to incorporate into the reforming nucleoli
during telophase.
 
Results and discussion
 
Establishment of a stable cell line expressing 
EGFP–topoII
 
 
 
To track the localization and dynamics of topoII
 
 
 
 in unper-
turbed living cells, we constructed a stable cell line, called
GT2-LPk, that constitutively expresses EGFP–topoII
 
 
 
. The
overexpression of active topoII is cytotoxic, and although
transient expression is possible, it has not previously been
possible to obtain stable lines that constitutively express
tagged forms of the enzyme (Mo et al., 1998; Mo and Beck,
1999). We compared the expression levels of endogenous to-
poII
 
 
 
 in the parental LLC-Pk and GT2-LPk lines. We found
that expression of endogenous topoII
 
 
 
 was diminished in the
GT2-LPk line, presumably accounting for the ability of the
GT2-LPk line to escape cytotoxicity from topoII
 
 
 
 overex-
pression (Fig. 1 A). Immunoprecipitated EGFP–topoII
 
 
 
 effi-
ciently catalyzed decatenation of kinetoplast DNA (Fig. 1 B).
EGFP–topoII
 
 
 
 bound to protein A beads showed equivalent
or greater catalytic activity compared with purified human
topoII
 
 
 
, a gift from Dr. Neal Osheroff (Vanderbilt Univer-
sity, Nashville, TN) (unpublished data).
 
EGFP–topoII
 
 
 
 localization in living cells
 
In living cells in interphase, EGFP-topoII
 
 
 
 was present dif-
fusely in the nucleoplasm and concentrated in the nucleoli (Fig.
1 C). Nucleolar labeling persisted through early prophase when
concentration of EGFP-topoII
 
 
 
 on chromosomes and at kinet-
ochores became apparent. In living cells during prometaphase
and metaphase topoII
 
 
 
 localized to thin lines running down
the lengths of the chromosome arms (Fig. 1 C). Higher resolu-
tion images in fixed cells revealed that EGFP-topoII
 
 
 
 was con-
centrated along the central axis of each chromatid arm (Fig. 1
D). This distribution is consistent with the axial distribution of
topoII observed in immunolabeling studies of fixed mamma-
lian cells and isolated chromosomes (Earnshaw and Heck,
1985; Gorbsky, 1994; Rattner et al., 1996; Sumner, 1996). In
anaphase, centromere concentration diminished while the lo-
Figure 1. GT2-LPk cells express EGFP-
topoII . (A) Immunoblotting with anti-
topoII  antibody of whole-cell extracts 
of parental LLC-Pk cells and GT2-LPk. 
GT2-LPk cells show downregulated 
expression of endogenous topoII . 
(B) EGFP–topoII  immunoprecipitated 
from GT2-LPk cells catalyzes decatenation 
of kinetoplast DNA. Lanes contain 
respectively decatenated control, 
kinetoplast DNA with no topoisomerase 
II added, and two separate immuno-
precipitations of GT2-LPk extracts with 
anti-GFP antibody. Arrows indicate the 
migration of the decatenated products 
(nicked and supercoiled). (C) EGFP–
topoII  localization in a panel of living 
cells at various stages of mitosis. EGFP–
topoII  associates with chromosomes in 
prophase, becomes concentrated at 
kinetochores (closed arrows) and along 
chromosome arms in prometaphase and 
metaphase, and associates with 
chromosome arms in anaphase. In late 
anaphase and telophase, EGFP–topoII  
increases in the cytoplasm with some 
becoming concentrated in cytoplasmic 
foci (open arrow). (D) Imaging of fixed 
GT2-LPk cell at late prometaphase after 
staining with DAPI shows localization of 
topoisomerase II to the kinetochore region 
and axes of chromosomes. Cells were 
simultaneously fixed and permeabilized 
by treatment with 2% formaldehyde, 
0.5% TX-100 in microtubule stabilizing 
buffer (60 mM Pipes, 25 mM Hepes, 10 
mM EGTA, 4 mM MgSO4, pH 6.95). The 
images represent a maximum projection 
of six 0.2- m optical sections. In the 
merged image, EGFP–topoII  is green 
and appears yellow due to overlap with 
the DNA in red. Bars, 10  m. 
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calization to the chromosome arms persisted. In late anaphase
and telophase, cytoplasmic levels of topoII
 
 
 
 increased similar
to the behavior of rhodamine-labeled topoII in 
 
Drosophila
 
(Swedlow et al., 1993). The anaphsase and telophase dynamics
of topoII
 
 
 
 may also be preliminary to the decrease in topoII
 
 
 
protein stability that occurs after mitosis (Heck et al., 1988). In
contrast to a previous immunolabeling study (Barthelmes et al.,
2000), we never observed concentration of EGFP-topoII
 
 
 
 at
centrosomes at any stage of the cell cycle.
In late anaphase we observed a novel concentration of to-
poII
 
 
 
 in cytoplasmic foci (Figs. 1 C, telophase, and 2 A
[Video 1, available at http://www.jcb.org/cgi/content/full/
jcb.200202053/DC1]). The foci were motile and appeared
to move toward and fuse with the reforming nuclei in telo-
phase. During telophase, most cytoplasmic topoII
 
 
 
 appeared
to reenter the forming nuclei, and the concentration of
EGFP–topoII
 
 
 
 in the nucleoli reappeared. The approximate
size, behavior, and appearance of the cytoplasmic EGFP–
topoII
 
 
 
-containing foci were reminiscent of previously de-
scribed dynamic structures termed nucleolus-derived foci
(NDF) (Dundr et al., 2000). These cytoplasmic NDFs ap-
parently travel to nuclei where they fuse with other nucleolar
precursors within the nuclei, e.g., prenucleolar bodies, to re-
form the interphase nucleoli (Olson et al., 2000). We found
that EGFP–topoII
 
 
 
 foci colocalized with antibody to B23, a
known component of the NDFs (Fig. 2 B). In contrast,
EGFP–topoII
 
 
 
 in anaphase and telophase GT2-LPk cells did
not colocalize with nuclear pore antigens (Fig. 2 C).
 
TopoII
 
 
 
 exchanges rapidly in mitotic chromosomes
 
To quantify topoII
 
 
 
 exchange in living cells in mitosis, we
used FRAP. If topoII
 
 
 
 served a static structural or nucleo-
Figure 2. EGFP–topoII  localization is 
dynamic at anaphase and telophase. 
(A) Selected frames from a time-lapse 
video of a GT2-LPk cell in late mitosis. 
In anaphase, some of the cytoplasmic 
EGFP–topoII  concentrates into distinct 
foci (closed arrows) that are motile. At 
telophase, the foci appear to fuse with 
the reforming nucleus (open arrows), 
whereas nucleoli become more apparent. 
(Image frames in this sequence were 
individually adjusted for contrast to 
optimize visualization of the cyto-
plasmic foci; Video 1, available at
http://www.jcb.org/cgi/content/full/
jcb.200202053/DC1) (B) EGFP–topoII  
foci (arrows) in telophase cells colocalize 
with NDFs identified by labeling with 
antibody to nucleolar B23 protein, a gift 
from Dr. Mirek Dundr (National Cancer 
Institute, Bethesda, MD). (The EGFP–
topoII  image is oversaturated for the 
nuclear fluorescence to clearly visualize 
the cytoplasmic foci.) (C) EGFP–topoII  
foci do not colocalize with reforming 
nuclear envelope identified by RL1 
antibody to nuclear pore proteins, a gift 
from Dr. Bryce Pascal (University of 
Virginia, Charlottesville, VA). Bars, 10  m.
 
Table I. 
 
Recovery of EGFP–topoII
 
 
 
 after photobleaching at kinetochores and chromosome arms
Structure t1/2 s (SD) Range % recovery (SD) Range
 
n
 
Kinetochore 15.7 (4.7) 9.0–22.4 61.9 (14.7) 42.8–86.7 8
Chromosome arm 15.5 (3.6) 9.9–22.5 75.9 (13.0) 52.4 – 90.0 10
Kinetochores and chromosome arms of GT2-LPk cells were photobleached with a nitrogen dye laser. Recovery of fluorescence was measured in the
photobleached area from images taken at intervals after photobleaching. After correcting for background and loss of fluorescence due to image capture,
measurements were used to calculate halftime recovery (t 1/2) and the percentage of recovery. 
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skeletal role in maintaining the organization of the kineto-
chore or chromosome arm, then recovery should be slow.
We found that recovery of the majority of the EGFP–
topoII
 
 
 
 at kinetochores and chromosome arms occurs rap-
idly (Fig. 3 and Table I). Because the average recovery was
 
 
 
100%, there may be a subpopulation of kinetochore and
chromosome-associated topoII
 
 
 
 that is more stably associ-
ated (for kinetochores an average of 38%; for chromosome
arms an average of 24%). We found that the exchange of to-
poII
 
 
 
 occurred at all stages of mitosis and did not differ
markedly from prophase through anaphase (Fig 3). Recov-
ery of fluorescence likely reflects rapid exchange between the
pools of topoII
 
 
 
 bound at chromosomes and kinetochores
with the pool of cytoplasmic topoII
 
 
 
.
The rapid exchange of the majority of topoII
 
 
 
 in vivo
contrasts to the tight association of topoII
 
 
 
  in chromo-
somes isolated from mitotic cells. In isolated chromosomes,
topoII is resistant to DNAse treatment and extraction with
high salt, and has thus been proposed to function as part of
a stable structural scaffold for the mitotic chromosome. Al-
though there may be a minor population of topoII that is
stably associated with chromatin, we find the majority to
exchange rapidly with topoII
 
 
 
 in the cytoplasm. Thus, in
vivo, it appears unlikely that the bulk of topoII
 
 
 
 serves a
static nucleoskeletal role in maintaining mitotic chromo-
some structure.
 
Rapid exchange of topoII
 
 
 
 requires catalytic activity
 
To determine whether catalytic activity of topoII
 
 
 
 was re-
quired for the rapid exchange observed in our FRAP anal-
yses, we used a chemical topoII
 
 
 
  inhibitor, ICRF-187.
ICRF-187 is an inhibitor of the bisdioxopiperazine class that
blocks the enzyme by trapping it in the postcleavage closed
clamp form (Roca et al., 1994). Applied to cells in mitosis,
this inhibitor inhibits chromosome condensation and in-
duces massive failure of chromosome segregation at ana-
phase in LLC-Pk cells, the parental line of the GT2-LPk
cells (Gorbsky, 1994). Similarly, we found that ICRF-187
inhibits normal chromosome condensation and chromo-
some segregation in GT2-LPk cells (Fig. 4, A and B). In mi-
totic cells treated with ICRF-187, we detected only minimal
recovery of EGFP–topoII
 
 
 
 into the bleached areas over a
10-min period (Fig. 4 C).
To corroborate the effects of ICRF-187 on the dynamics
of topoII
 
 
 
 in mitotic cells, we also tested its effects in inter-
phase nuclei. Treatment of cells with ICRF-187 greatly di-
minished the level of EGFP–topoII
 
 
 
 concentrated in the
nucleolus. When tested by FRAP analysis of interphase cells,
Figure 3. Recovery of EGFP–topoII  fluorescence after photobleaching occurs rapidly at kinetochores and chromosome arms. Examples 
showing targeting of kinetochores (arrows) at prophase (A) and prometaphase (B) and targeting of chromosome arms (arrows) at metaphase 
(C) and anaphase (D) Images include a prebleach image, one taken just after photobleaching (0 time) and two images taken during recovery. 
Graphs at the end of each sequence show fitting of corrected intensity measurements in the photobleached regions to determine recovery half 
times (t-1/2) and total degree of recovery (recovery). Bars, 10  m. 
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again ICRF-187 treatment was found to cause a marked de-
crease in the rate and extent of fluorescence recovery when
compared with nondrug-treated interphase cells (Fig. 4, C
and D). Together, these results suggest that the rapid ex-
change noted for EGFP–topoII
 
 
 
 in unperturbed cells re-
quires catalytic activity. Moreover, ICRF-187 treatment
slows the exchange rate of EGFP–topoII
 
 
 
,
 
 
 
lending further
support to the idea that the EGFP–topoII
 
 
 
 protein is func-
tional in vivo.
 
Rapid exchange of chromosome-associated and 
cytoplasmic pools of topoII
 
To further test whether the rapid exchange of topoII
 
 
 
 was
somehow restricted to the protein associated with the chro-
mosomes or occurred by exchange with a soluble cytoplas-
mic pool, we used fluorescence loss in photobleaching. We
repeatedly photobleached a small area in the cytoplasm (Fig.
5 A) or on one region of the chromosomes of cells treated
with a microtubule inhibitor to inhibit chromosome move-
ment (Fig. 5 B; Video 2, available at http://www.jcb.org/cgi/
content/full/jcb.200202053/DC1). Loss of fluorescence of
EGFP–topoII
 
 
 
 from unbleached mitotic chromosomes oc-
curred upon repetitive bleaching at the distant area (Fig. 5).
These data demonstrate that topoII
 
 
 
 mobility is not region-
ally confined. TopoII
 
 
 
 associated with chromosomes and
kinetochores is mobile and exchanges with cytoplasmic
pools of the enzyme.
Another study recently appeared analyzing GFP deriva-
tives of topoII
 
 
 
  and topoII
 
 
 
  in stable lines of 293 cells
(Christensen et al., 2002). In general, the results from these
authors and ours are consistent in describing the overall lo-
calization of topoII
 
 
 
 in interphase and mitotic cells. Both
studies also agree that most topoII
 
 
 
  undergoes rapid ex-
change with the cytoplasm, and the studies concur on the
necessity for topoII
 
 
 
  catalytic activity in rapid exchange.
The studies do differ with regard to certain conclusions re-
garding topoII
 
 
 
 in mitotic chromosomes. Whereas Chris-
tensen et al. (2002) report that nearly 100% of topoII
 
 
 
turns over rapidly, our results indicate that a population of
topoII
 
 
 
 associated with the kinetochores and chromosome
Figure 4. Catalytic activity of topoII  is required for rapid recovery after photobleaching. (A and B) GT2-LPk cells treated with ICRF-187, 
an inhibitor of topoII , showed impaired chromosome condensation in prometaphase (A) and mitotic catastrophe as the cleavage furrow has 
cut through the mass of unseparated chromatids in telophase (B, arrow). (C) Photobleaching of mitotic cells shows very limited recovery 
(arrow). (D) Photobleaching of interphase nucleus of ICRF-187–treated cell also shows limited recovery. ICRF-187 treatment reduces the 
concentration of EGFP-topoII  at the nucleoli. (E) Photobleaching of nondrug treated interphase cell nucleus results in rapid recovery (arrow). 
Bars, 10  m. 
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arms turns over more slowly. Moreover, whereas Chris-
tensen et al. (2002) conclude that in living cells topoII
 
 
 
 is
uniformly distributed across the width of the chromosome
arms, our evidence favors the idea that topoII
 
 
 
 concentrated
toward the axes of the arms. There are several potential
sources for the differences in the two studies. Apart from in-
herent differences between the two parental cell lines (LLC-
Pk vs. 293), the GT2-LPk derivative line used in our work
has downregulated levels of endogenous topoII
 
 
 
 that is
replaced by EGFP–topoII
 
 
 
. The 293 cell derivatives of
Christensen et al. (2002) did not show evidence of down
regulation of the endogenous enzyme. In addition, the pho-
tobleaching studies of mitotic chromosomes performed by
Christensen et al. (2002) were carried out on cells arrested at
M phase by treatment with the microtubule stabilizer pacli-
taxel. Apart from the cell shown in Fig. 5 B, our studies were
done on cells not treated with drugs. In preliminary studies,
we have noted greater recovery of EGFP–topoII
 
 
 
 after pho-
tobleaching GT2-LPk cells treated with either paclitaxel or
nocodazole (unpublished data). Full resolution of the differ-
ences between the two studies will require further investiga-
tion.
 
Conclusions
 
Cell fractionation studies originally suggested that the bulk
of topoII
 
 
 
 in mitotic cells was stably associated with the mi-
totic chromosomes and formed a structural scaffold. Al-
though our evidence of rapid exchange of the bulk of chro-
mosome-associated topoII does not rule out a structural role
for the enzyme, any such role must accommodate the fact
that most of the protein is highly dynamic, exchanging with
the soluble pool in seconds. Consistent with the earlier find-
ings on the single isoform of topoII in 
 
Drosophila
 
 embryos
(Swedlow et al., 1993), we find in mammalian cells a net
movement of topoII  from the chromosomes to the cyto-
plasm in anaphase. However, two-way exchange between
the chromosome arms and cytoplasm persists during ana-
phase. We report a novel association of topoII  with NDFs
in late mitosis. These organelles may serve to accumulate
proteins to newly forming nucleoli in the daughter cells. The
rapid dynamics of topoII  throughout the mitotic chromo-
somes may be essential in allowing the enzyme to reach and
rapidly relieve strain before torsional stresses imparted by
chromosome condensation and chromosome movements
cause breaks to the DNA.
Materials and methods
Cell culture and immunofluorescence
LLC-Pk were grown in DME supplemented with 10% FBS and antibiotics.
To produce a stable cell line expressing EGFP–topoII , LLC-Pk cells were
transfected using Lipofectamine Plus according to the manufacturer’s in-
structions. Cells were selected for resistance to 2  g/ml G418 and cloned
by dilution in microwell plates. Cells were processed for immunofluores-
cence using methods described previously (Kallio et al., 1998).
Immunoprecipitation and decantenation assays
GT2-LPk cells were lysed in high salt buffer (20 mM Tris, pH 8.0, 0.75 M
KCl, 0.75% NP40) and immunoprecipitated with anti-GFP antibody using
previously described methods (Kallio et al., 1998). Decatenation assays
were performed using a kit supplied by Topogen according to the manu-
facturer’s directions.
Western blotting
Proteins were separated by SDS polyacrylamide gel electrophoresis using
4–20% gradient acrylamide gels. Proteins were transferred to Immobilon-P
Figure 5. Fluorescence loss in photobleaching demonstrates exchange of topoII  between chromosomal and cytoplasmic pools in mitotic 
cells. (A) Exchange of topoII  occurs between the chromosomes and the cytoplasm of mitotic cells. A late prometaphase cell outlined by the 
solid line was targeted for photobleaching in the cytoplasm away from the chromosomes indicated (dotted circle). The region was photobleached 
every 20 s and images were captured every 2 min. Repeated photobleaching of the cytoplasm results in depletion of fluorescence in the 
chromosomes. The fluorescence intensity of the chromosomes was reduced by 79%, whereas that of the control interphase nucleus (arrow) 
in the adjacent interphase cell was reduced only 8%. (B) Exchange of topoII  occurs through the cytoplasm among chromosomes. A cell 
treated with 0.1  g/ml nocodazole was repeatedly bleached in the lower region of the mass of chromosomes (dotted circle). Fluorescence 
intensity of the isolated chromosome at top (closed arrows) diminished by 85%, whereas the intensity of the nucleus in the neighboring cell 
(open arrow) decreased by only 5% over the course of the observations (Video 2, available at http://www.jcb.org/cgi/content/full/
jcb.200202053/DC1). Bars, 10  m. Rapid dynamics of topoisomerase II  in mitosis | Tavormina et al. 29
membrane. Anti-topoII  was used at 1:1,000. Blots were then incubated
with HRP-conjugated goat anti–rabbit and proteins visualized by chemilu-
minescence and imaged with a digital camera.
Laser photobleaching
Cells were observed on a warm stage using a Zeiss Axioplan II microscope
equipped with the ORCA II CCD camera (Hamamastu) and controlled
with MetaMorph software (Universal Imaging Corporation). A nitrogen la-
ser-pumped dye laser (Photonic Instruments) delivered 4 ns laser pulses at
440 nm attenuated with a neutral density slider. Typically, we bleached for
1 s at a repetition rate of 30 Hz. For each time-lapse series in Figs. 3, 4,
and 5, the individual frames were imaged and adjusted for contrast using
identical conditions.
Data analysis
Metamorph software was used for data collection and analysis. Data were
analyzed essentially as described (Gorbsky et al., 1990;  Howell et al.,
2000; Phair and Misteli, 2000). Briefly, an area slightly larger than the tar-
get area was used for local cytoplasmic background subtraction. Integrated
intensity of the target and background regions and their associated area
measurements were logged to Excel spreadsheets. Acquisitions were nor-
malized to adjust for reduction of total cellular fluorescence due to pho-
tobleaching and image acquisition (Phair and Misteli, 2000). Normalized
relative fluorescence intensity values were exported to GraphPad Prism
software and analyzed by nonlinear regression. The rate constant k was
determined using the perturbation-relaxation equation and half time of re-
covery was determined using t1/2   ln2/k. Percent recovery was calculated
according to the method described by Howell et al. (2000) using normal-
ized relative intensity values.
Online supplemental material
Videos 1 and 2, corresponding to Figs. 2 A and Fig. 5 B, respectively, are
available online as Quicktime movies at http://www.jcb.org/cgi/content/
full/jcb.200202053/DC1.
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